Thr92Ala-DIO2 heterozygosity is associated with skeletal muscle mass and myosteatosis in patients with COVID-19.

Fabyan Esberard de Lima BeltrãoDaniele Carvalhal de Almeida BeltrãoGiulia CarvalhalFabyanna Lethicia de Lima BeltrãoJocyel de Brito OliveiraHatilla Dos Santos SilvaHelena Mariana Pitangueira TeixeiraJuliana Lopes RodriguesCamila Alexandrina Viana de FigueiredoRyan Dos Santos CostaFabio HechtGiciane Carvalho VieiraMaria da Conceição Rodrigues GonçalvesAntonio C BiancoHelton Estrela Ramos

Published in: European thyroid journal (2024)

Thr92Ala-DIO2 heterozygosity is associated with increased skeletal MA and less myosteatosis in patients with COVID-19. The protective effect of Thr92Ala-DIO2 heterozygosity on COVID-19 mortality is restricted to patients with reduced MA.

Keyphrases

coronavirus disease
sars cov
cardiovascular events
risk factors
cardiovascular disease
type diabetes
respiratory syndrome coronavirus